Gaps tend to get filled. But here? That means going down to around 60 percent of cash. That's absurd. Just so the market can compulsively "fill the gap"? I would think a natural tension should develop between that tendency and those who recognize the incredible value here and put upward pressure on the price. We'll se what happens.
Of note was that the MILO study was Binimetinib versus Chemo, NOT Binimetinib plus Chemo versus Chemo alone. It was active drug versus active drug, rather than a combination. So the read-through to other studies is limited. MEK inhibitors work. Because of trial design and previous phase 2 work I believe that the other studies for both Binimetinib and Selumetinib are more likely in to show positive results.